TRACER
- 10,000 participants
- 12 sites in New Zealand
- 800 sites globally
A Multi-centre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRAâ?¢CER)
This is a phase III randomised, multicentre, double-blind, placebo-controlled, balanced-parallel-groups study involving the use of an investigational drug SCH 530348. This study will evaluate the safety and efficacy of SCH 530348 in addition to the standard of care in participants with atherosclerotic disease/acute coronary syndrome (ACS) and determine if there is a clinical benefit relative to standard of care alone.